Lobaplatin D 19466

Drugs in R and D

Volumn 4, Issue 6, 2003, Pages 369-372

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CISPLATIN; LOBAPLATIN; METHOTREXATE; PLATINUM COMPLEX; PLATINUM DERIVATIVE; VINBLASTINE;

AGRANULOCYTOSIS; ANEMIA; AREA UNDER THE CURVE; ARTICLE; AUSTRALIA; BLADDER CANCER; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAZIL; BREAST CANCER; CANCER CHEMOTHERAPY; CHINA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTRACT; DIARRHEA; DNA ALKYLATION; DRUG ACTIVITY; DRUG APPROVAL; DRUG ELIMINATION; DRUG EXCRETION; DRUG MANUFACTURE; DRUG MARKETING; ESOPHAGUS CANCER; EUROPEAN UNION; FEE; GASTROINTESTINAL TOXICITY; GENE THERAPY; GERM CELL TUMOR; GRANULOCYTOPENIA; HUMAN; INFECTION; INOPERABLE CANCER; LEUKOPENIA; LIVER DISEASE; LUNG CANCER; LUNG CARCINOMA; LUNG SMALL CELL CANCER; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; PROTEINURIA; SOLID TUMOR; SOUTH AFRICA; TECHNOLOGY; THROMBOCYTOPENIA; UNITED STATES;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CLINICAL TRIALS; CYCLOBUTANES; HUMANS; NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 0242521533     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200304060-00008     Document Type: Article

References (11)

1. AEterna Laboratories Inc. AEterna-subsidiary Zentaris AG Signs Product Partnership for Novel Platinum Cancer Drug in China. Media Release: 8 Jan 2003. Available from URL: http://www.aeterna.com
2. Mross K, Meyberg L, Fiebig H. Pharmacokinetics of the platinum derivative D-19466. European Journal of Cancer 27 (Suppl. 2): 197, 1991
3. Gietema JA, Veldhuis G-J, Guchelaar H-J, et al. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. British Journal of Cancer 71: 1302-1307, Jun 1995
4. Welink J, Vermorken JB, Boven E. Pharmacokinetics of lobaplatin in patients with advanced solid tumors, including patients with impaired renal or liver function. 88th Annual Meeting of the American Association for Cancer Research: 223, 12 Apr 1997
5. Gietema JA, de Vries EGE, Sleijfer DTh, et al. A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. British Journal of Cancer 67: 396-401, Feb 1993
6. Gietema JA, Guchelaar H-J, de Vries EGE, et al. A phase I study of lobaplatin (D-19466) administered by 72 h continuous infusion. Anti-Cancer Drugs 4: 51-55, Feb 1993
7. Fiebig HH, Henss H, von Pawel I, et al. Phase II clinical trial of lobaplatin (D-19466) in pretreated patients with small-cell lung cancer. Onkologie 19: 328-332, Aug 1996
8. Kavanagh JJ, Edwards CL, Freedman RS, et al. A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer. Gynecologic Oncology 58: 106-109, Jul 1995
9. Jung P, Bachmann P, Burk K, et al. Lobaplatin in combination with methotrexate and vinblastine in patients with transitional cell carcinoma of the urinary tract - a pilot phase I/(II) study. European Journal of Cancer: Part A 31A: 1891-1892, Oct 1995
10. Degardin M, Armand JP, Chevallier B, et al. A Clinical Screening Cooperative Group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer. Investigational New Drugs 13: 253-255, No. 3, 1995
11. Harstrick A, Scharnofske M, Hapke G. In vitro antitumor activity of lobaplatin in cisplatin sensitive and resistant human carcinoma cell lines. Annals of Oncology 3 (Suppl. 5): 50, Nov 1992